285 related articles for article (PubMed ID: 24057669)
41. Lyso-GM2 ganglioside: a possible biomarker of Tay-Sachs disease and Sandhoff disease.
Kodama T; Togawa T; Tsukimura T; Kawashima I; Matsuoka K; Kitakaze K; Tsuji D; Itoh K; Ishida Y; Suzuki M; Suzuki T; Sakuraba H
PLoS One; 2011; 6(12):e29074. PubMed ID: 22205997
[TBL] [Abstract][Full Text] [Related]
42. Epstein-Barr virus transformed lymphoid cell lines as a new model system in culture for the study of GM2-gangliosidoses: Tay-Sachs and Sandhoff diseases.
Maret A; Salvayre R; Negre A; Bes JC; Douste-Blazy L
Biol Cell; 1985; 53(3):293-6. PubMed ID: 2990625
[TBL] [Abstract][Full Text] [Related]
43. Therapeutic response in feline sandhoff disease despite immunity to intracranial gene therapy.
Bradbury AM; Cochran JN; McCurdy VJ; Johnson AK; Brunson BL; Gray-Edwards H; Leroy SG; Hwang M; Randle AN; Jackson LS; Morrison NE; Baek RC; Seyfried TN; Cheng SH; Cox NR; Baker HJ; Cachón-González MB; Cox TM; Sena-Esteves M; Martin DR
Mol Ther; 2013 Jul; 21(7):1306-15. PubMed ID: 23689599
[TBL] [Abstract][Full Text] [Related]
44. Patient and caregiver perspectives on burden of disease manifestations in late-onset Tay-Sachs and Sandhoff diseases.
Lyn N; Pulikottil-Jacob R; Rochmann C; Krupnick R; Gwaltney C; Stephens N; Kissell J; Cox GF; Fischer T; Hamed A
Orphanet J Rare Dis; 2020 Apr; 15(1):92. PubMed ID: 32295606
[TBL] [Abstract][Full Text] [Related]
45. The GM2 gangliosidoses databases: allelic variation at the HEXA, HEXB, and GM2A gene loci.
Cordeiro P; Hechtman P; Kaplan F
Genet Med; 2000; 2(6):319-27. PubMed ID: 11339652
[TBL] [Abstract][Full Text] [Related]
46. Direct Intracranial Injection of AAVrh8 Encoding Monkey β-N-Acetylhexosaminidase Causes Neurotoxicity in the Primate Brain.
Golebiowski D; van der Bom IMJ; Kwon CS; Miller AD; Petrosky K; Bradbury AM; Maitland S; Kühn AL; Bishop N; Curran E; Silva N; GuhaSarkar D; Westmoreland SV; Martin DR; Gounis MJ; Asaad WF; Sena-Esteves M
Hum Gene Ther; 2017 Jun; 28(6):510-522. PubMed ID: 28132521
[TBL] [Abstract][Full Text] [Related]
47. GM2 gangliosidosis variant B1 neuroradiological findings.
Grosso S; Farnetani MA; Berardi R; Margollicci M; Galluzzi P; Vivarelli R; Morgese G; Ballestri P
J Neurol; 2003 Jan; 250(1):17-21. PubMed ID: 12527987
[TBL] [Abstract][Full Text] [Related]
48. The clinical aspects of adult hexosaminidase deficiencies.
Federico A; Palmeri S; Malandrini A; Fabrizi G; Mondelli M; Guazzi GC
Dev Neurosci; 1991; 13(4-5):280-7. PubMed ID: 1840098
[TBL] [Abstract][Full Text] [Related]
49. Assay of the GM2-ganglioside cleaving hexosaminidase activity of skin fibroblasts for GM2-gangliosidoses.
Harzer K
Clin Chim Acta; 1983 Nov; 135(1):89-93. PubMed ID: 6228344
[No Abstract] [Full Text] [Related]
50. Neuronal accumulation of alpha- and beta-synucleins in the brain of a GM2 gangliosidosis mouse model.
Suzuki K; Iseki E; Katsuse O; Yamaguchi A; Katsuyama K; Aoki I; Yamanaka S; Kosaka K
Neuroreport; 2003 Mar; 14(4):551-4. PubMed ID: 12657883
[TBL] [Abstract][Full Text] [Related]
51. L-Arginine Ameliorates Defective Autophagy in GM2 Gangliosidoses by mTOR Modulation.
Castejón-Vega B; Rubio A; Pérez-Pulido AJ; Quiles JL; Lane JD; Fernández-Domínguez B; Cachón-González MB; Martín-Ruiz C; Sanz A; Cox TM; Alcocer-Gómez E; Cordero MD
Cells; 2021 Nov; 10(11):. PubMed ID: 34831346
[TBL] [Abstract][Full Text] [Related]
52. Promoters for the human beta-hexosaminidase genes, HEXA and HEXB.
Norflus F; Yamanaka S; Proia RL
DNA Cell Biol; 1996 Feb; 15(2):89-97. PubMed ID: 8634145
[TBL] [Abstract][Full Text] [Related]
53. Mice lacking both subunits of lysosomal beta-hexosaminidase display gangliosidosis and mucopolysaccharidosis.
Sango K; McDonald MP; Crawley JN; Mack ML; Tifft CJ; Skop E; Starr CM; Hoffmann A; Sandhoff K; Suzuki K; Proia RL
Nat Genet; 1996 Nov; 14(3):348-52. PubMed ID: 8896570
[TBL] [Abstract][Full Text] [Related]
54. Biochemical and molecular aspects of late-onset GM2-gangliosidosis: B1 variant as a prototype.
Suzuki K; Vanier MT
Dev Neurosci; 1991; 13(4-5):288-94. PubMed ID: 1840099
[TBL] [Abstract][Full Text] [Related]
55. Mouse model of GM2 activator deficiency manifests cerebellar pathology and motor impairment.
Liu Y; Hoffmann A; Grinberg A; Westphal H; McDonald MP; Miller KM; Crawley JN; Sandhoff K; Suzuki K; Proia RL
Proc Natl Acad Sci U S A; 1997 Jul; 94(15):8138-43. PubMed ID: 9223328
[TBL] [Abstract][Full Text] [Related]
56. Therapeutic benefit after intracranial gene therapy delivered during the symptomatic stage in a feline model of Sandhoff disease.
McCurdy VJ; Johnson AK; Gray-Edwards HL; Randle AN; Bradbury AM; Morrison NE; Hwang M; Baker HJ; Cox NR; Sena-Esteves M; Martin DR
Gene Ther; 2021 Apr; 28(3-4):142-154. PubMed ID: 32884151
[TBL] [Abstract][Full Text] [Related]
57. beta-hexosaminidase lentiviral vectors: transfer into the CNS via systemic administration.
Kyrkanides S; Miller JH; Brouxhon SM; Olschowka JA; Federoff HJ
Brain Res Mol Brain Res; 2005 Feb; 133(2):286-98. PubMed ID: 15710246
[TBL] [Abstract][Full Text] [Related]
58. Glycosphingolipid degradation and animal models of GM2-gangliosidoses.
Kolter T; Sandhoff K
J Inherit Metab Dis; 1998 Aug; 21(5):548-63. PubMed ID: 9728335
[TBL] [Abstract][Full Text] [Related]
59. Life-Limiting Peripheral Organ Dysfunction in Feline Sandhoff Disease Emerges after Effective CNS Gene Therapy.
Johnson AK; McCurdy VJ; Gray-Edwards HL; Maguire AS; Cochran JN; Gross AL; Skinner HE; Randle AN; Shirley JL; Brunson BL; Bradbury AM; Leroy SG; Hwang M; Rockwell HE; Cox NR; Baker HJ; Seyfried TN; Sena-Esteves M; Martin DR
Ann Neurol; 2023 Nov; 94(5):969-986. PubMed ID: 37526361
[TBL] [Abstract][Full Text] [Related]
60. GM2 gangliosidoses: a review of cases confirmed by beta-N-acetylhexosaminidase assay.
Christopher R; Rangaswamy GR; Shetty KT
Indian J Pediatr; 1995; 62(4):479-83. PubMed ID: 10829909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
